c O M M e n ta rY
In response to the ongoing debate regarding the optimum extent of pelvic lymph node dissection (LND) in patients undergoing radical cystectomy, Dhar et al. 1 have compared survival and recurrence in two consecutive series of patients with muscle-invasive bladder cancer (stage pT2-3, pN0-2) who received either a 'limited' or an 'extended' pelvic LND. Limited pelvic LND was performed in 336 patients at the Cleveland Clinic, OH, USA, and extended pelvic LND in 322 patients at the University of Bern, Switzerland. The 5-year recurrencefree survival for pT2, pN0-2 disease was 63% for limited versus 71% for extended LND (P = 0.22), and for pT3, pN0-2 disease was 19% versus 49% (P <0.0001). Although these results must be viewed with caution, owing to the nonrandomized, two-institution, retrospective nature of this analysis, they suggest that extended pelvic LND improves outcomes in patients undergoing radical cystectomy for muscle-invasive bladder cancer.
The first point to make is that the terms 'extended' and 'limited' pelvic LND used in the paper by Dhar et al. 1 are misleading, since they do not correspond to the commonly used anatomical SUMMARY This Practice Point commentary discusses the paper by Dhar and colleagues, which compared outcomes between two cohorts of patients with muscle-invasive bladder cancer who received either 'limited' pelvic lymph node dissection (LND) or 'extended' pelvic LND at clinics in the US or Switzerland. The patients who received extended LND demonstrated improved overall and recurrence-free survival. Notably, however, the 'extended' and 'limited' dissections utilized in this study do not correspond to the commonly used anatomical templates defined by these terms. Nonetheless, despite this and other methodological limitations, this study does add to the growing evidence supporting the use of more-extensive pelvic LND in this setting. One prospective, randomized trial aiming to address this issue is currently accruing patients in Germany. While results are awaited, extended LND should be regarded as an essential component of radical cystectomy and applied to all patients undergoing radical surgery for bladder cancer.
Keywords bladder cancer, cystectomy, extended, limited, lymph node dissection
templates defined by these terms. 'Subtotal extended' and 'standard' pelvic LND might represent more-fitting terms for the templates used in Bern and at the Cleveland Clinic. The surgical boundaries of the conventional extended pelvic LND were originally detailed by Leadbetter and Cooper. 2 This dissection is bounded proximally by the distal aorta, laterally by the genitofemoral nerve, distally by the circumflex iliac vein and Cloquet's lymph node and posteriorly by the internal iliac vessels, including the presacral and presciatic nodes, and those in the obturator fossa. By contrast, the dissection used in Bern is bounded cephalad by the ureteric crossing of the common iliac vessels (approximately at the middle of the common iliac vessels), with similar lateral and distal boundaries to the extended dissection. Accordingly, this dissection includes only a fraction of the common iliac, presacral and presciatic nodes covered by extended pelvic LND. The 'standard' pelvic LND used by the Cleveland Clinic in this study is bounded proximally by the bifurcation of the common iliac vessels; the distal and lateral boundaries are similar to those in the extended dissection. This dissection was introduced in the late 1980s because, in the absence of gross lymph node involvement, the lymph nodes above the common iliac bifurcation were rarely found to be involved. 3 It was introduced, however, without any demonstration that it offered longterm survival equivalent to extended pelvic LND. Finally, the conventional limited pelvic LND includes only the tissue medial to the external iliac vein and the obturator fossa.
Compared with the standard dissection of the Cleveland Clinic, the more-extensive pelvic LND performed in Bern resulted in a significant survival advantage for the entire population of patients with pT2 or pT3 tumors, not only for the subpopulations defined by presence or absence of pelvic lymph node involvement. Nevertheless, while both overall and recurrencefree survival of patients with pT3 tumors was substantially improved in Bern, overall survival was similar at the two institutions for patients with pT2 disease. Consequently, the conclusions of Dhar et al. 1 are based on the assumption that the pathological assessment of tumor invasion of the bladder wall into perivesical fat (i.e. pT3) was performed similarly at the two institutions. Discounting this potential source of error, the finding of a significant survival advantage for the entire population of a defined tumor stage dismisses stage migration (Will Rogers phenomenon) 4 as an explanation for the survival advantage, as a priori the true incidence of nodal involvement should be similar in patients with tumors of the same stage in Bern and Cleveland. The study corroborates the results of an earlier report that showed an almost 20% increase in 5-year recurrence-free survival for patients with tumors confined to the bladder wall who underwent an extended versus a standard pelvic LND. 5 Furthermore, multivariate analysis of the surgical factors associated with survival in the SWOG 8710 randomized trial showed that a more-extensive LND conferred a similar magnitude of survival advantage after adjustment for pathological factors and chemotherapy. 6 The survival benefit conferred by the moreextensive pelvic LND on the majority of patients without pathologically confirmed lymph node metastasis might be explained by the excision of tissue harboring subclinical metastasis detectable by polymerase chain reaction analysis but not by standard histopathology. After radical cystectomy with extended pelvic LND, 37% of patients with common iliac and para-aortic lymph node involvement outside the boundaries of the standard pelvic LND were disease-free at 5 years, underscoring the notion that the extended dissection might confer a survival benefit on patients with disease outside the boundaries of the standard pelvic LND. 7 In conclusion, the study by Dhar et al. 1 adds to the growing body of evidence supporting the supposition that a more-extensive pelvic LND improves patient survival after radical cystectomy. The available evidence, however, comes from retrospective cohort studies, and should be interpreted in this context. The standard of care for pelvic LND might be better defined by the prospective, randomized clinical trial (AB25/02) investigating survival after radical cystectomy with extended versus standard pelvic LND that is currently recruiting patients in Germany. 8 In the meantime, extended LND should be regarded as an essential component of radical cystectomy and applied to all patients undergoing radical surgery for bladder cancer, as it offers the best chance of survival. 
Practice Point
A more-extensive pelvic lymph node dissection (LND) improves survival following radical cystectomy, as well as providing more-accurate staging.
Results of randomized trials might better define the standard of care for LND in this setting. Meanwhile, extended LND should be regarded as an essential component of radical cystectomy for all patients undergoing radical surgery for bladder cancer.
